Patents Assigned to Revolo Biotherapeutics Limited
  • Method for the treatment of a relapsing-remitting condition
    Patent number: 11834478
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: December 5, 2023
    Assignee: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Method for the treatment of a relapsing-remitting condition
    Patent number: 11479585
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 25, 2022
    Assignee: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
    Patent number: 11098090
    Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 24, 2021
    Assignee: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper